Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I randomized, 2-panel, double-blind, placebo-controlled, adaptive design, safety and pharmacokinetics trial of islatravir administered using a polymer drug eluting implant

Next Previous
Search
Trial Profile

A Phase I randomized, 2-panel, double-blind, placebo-controlled, adaptive design, safety and pharmacokinetics trial of islatravir administered using a polymer drug eluting implant

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Islatravir (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept

Most Recent Events

  • 26 Jul 2019 New trial record
  • 23 Jul 2019 According to the Merck and Co media release, early findings from this trial were presented at the 10th International AIDS Society Conference on HIV Science (IAS 2019) in Mexico City and featured in the official IAS 2019 press program (Abstract TUAC0401LB).
  • 23 Jul 2019 Results presented in the Merck and Co media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top